









市场行情
/
股票
/
nasdaq-mnpr
/

Monopar Therapeutics Inc

MNPR

68.770USD

-2.010-2.84%

收盘 12/26, 16:00（美东）报价延迟15分钟

458.21M总市值

亏损市盈率 TTM



Monopar Therapeutics Inc

68.770

-2.010-2.84%

概览公司财务分析

概览

公司

财务

分析

关于 Monopar Therapeutics Inc 公司

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

Monopar Therapeutics Inc简介



公司代码MNPR

公司名称Monopar Therapeutics Inc

上市日期Dec 19, 2019

CEORobinson (Chandler D)

员工数量16

证券类型Ordinary Share

年结日Dec 19

公司地址1000 Skokie Blvd Ste 350

城市WILMETTE

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编60091-1146

电话18473880349

网址https://www.monopartx.com/

公司代码MNPR

上市日期Dec 19, 2019

CEORobinson (Chandler D)

Monopar Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Chandler D. Robinson, M.D.

Chief Executive Officer, Director

79.42K

+8.10%

Dr. Christopher M. (Chris) Starr, Ph.D.

Executive Chairman of the Board

16.05K

Ms. Lavina Talukdar

Independent Director

14.00K

Ms. Kim R. Tsuchimoto

Director

11.49K

Mr. Arthur J. Klausner

Independent Director

6.17K

Mr. Raymond William (Bill) Anderson

Independent Director

5.37K

Mr. Vu Quan

Chief Financial Officer, Principal Accounting Officer

Dr. Patrice P. Rioux, M.D., Ph.D.

Acting Chief Medical Officer

Mr. Andrew J. Cittadine

Chief Operating Officer

名称

名称/职务

职务

持股

持股变动

Dr. Chandler D. Robinson, M.D.

Chief Executive Officer, Director

79.42K

+8.10%

Dr. Christopher M. (Chris) Starr, Ph.D.

Executive Chairman of the Board

16.05K

Ms. Lavina Talukdar

Independent Director

14.00K

Ms. Kim R. Tsuchimoto

Director

11.49K

Mr. Arthur J. Klausner

Independent Director

6.17K

Mr. Raymond William (Bill) Anderson

Independent Director

5.37K

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月18日周二

持股股东

股东类型

持股股东

占比

Janus Henderson Investors

19.26%

Adage Capital Management, L.P.

9.86%

Gem Pharmaceuticals LLC

9.14%

RA Capital Management, LP

7.65%

AstraZeneca PLC

5.80%

其他

48.28%

持股股东

占比

Janus Henderson Investors

19.26%

Adage Capital Management, L.P.

9.86%

Gem Pharmaceuticals LLC

9.14%

RA Capital Management, LP

7.65%

AstraZeneca PLC

5.80%

其他

48.28%

股东类型

持股股东

占比

Investment Advisor/Hedge Fund

27.20%

Hedge Fund

19.02%

Corporation

19.01%

Investment Advisor

9.43%

Venture Capital

9.00%

Individual Investor

4.78%

Research Firm

0.24%

Pension Fund

0.07%

Bank and Trust

0.06%

其他

11.17%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

3.34M

50.46%

+135.23K

2025Q2

5.07M

82.91%

-355.61K

2025Q1

5.03M

83.96%

+455.96K

2024Q4

4.84M

79.28%

+1.76M

2024Q3

1.90M

50.69%

+25.14K

2024Q2

1.96M

52.51%

+123.52K

2024Q1

1.91M

52.92%

+136.66K

2023Q4

1.88M

67.20%

+125.61K

2023Q3

1.87M

67.45%

+153.91K

2023Q2

1.84M

66.75%

+138.58K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Janus Henderson Investors

1.17M

17.73%

+37.96K

+3.35%

Jun 30, 2025

Adage Capital Management, L.P.

599.20K

9.06%

Jun 30, 2025

Gem Pharmaceuticals LLC

611.08K

9.24%

Apr 04, 2025

RA Capital Management, LP

511.21K

7.73%

Jun 30, 2025

AstraZeneca PLC

387.33K

5.86%

+387.33K

Oct 23, 2024

Tactic Pharma LLC

272.03K

4.11%

-550.23K

-66.92%

Sep 24, 2025

The Vanguard Group, Inc.

86.49K

1.31%

+31.25K

+56.59%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

183.97K

2.78%

+175.22K

+2003.49%

Jun 30, 2025

持股ETF



更新时间: 12月2日周二

机构名称

占比

iShares Micro-Cap ETF

0.06%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.05%

Vanguard US Momentum Factor ETF

0.04%

iShares Russell 2000 Growth ETF

0.02%

Proshares Ultra Russell 2000

0.01%

Global X Russell 2000 ETF

0.01%

ProShares Hedge Replication ETF

0.01%

ProShares UltraPro Russell2000

0.01%

iShares Russell 2000 ETF

0.01%

Avantis US Small Cap Equity ETF

iShares Micro-Cap ETF

占比0.06%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

占比0.05%

Vanguard US Momentum Factor ETF

占比0.04%

iShares Russell 2000 Growth ETF

占比0.02%

Proshares Ultra Russell 2000

占比0.01%

Global X Russell 2000 ETF

占比0.01%

ProShares Hedge Replication ETF

占比0.01%

ProShares UltraPro Russell2000

占比0.01%

iShares Russell 2000 ETF

占比0.01%

Avantis US Small Cap Equity ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Aug 09, 2024

Merger

5→1

Aug 09, 2024

Merger

5→1

Aug 09, 2024

Merger

5→1

Aug 09, 2024

Merger

5→1

公告日期

类型

比率

Aug 09, 2024

Merger

5→1

Aug 09, 2024

Merger

5→1

Aug 09, 2024

Merger

5→1

Aug 09, 2024

Merger

5→1

常见问题

Monopar Therapeutics Inc的前五大股东是谁？



Monopar Therapeutics Inc 的前五大股东如下：
Janus Henderson Investors持有股份：1.17M，占总股份比例：17.73%。
Adage Capital Management, L.P.持有股份：599.20K，占总股份比例：9.06%。
Gem Pharmaceuticals LLC持有股份：611.08K，占总股份比例：9.24%。
RA Capital Management, LP持有股份：511.21K，占总股份比例：7.73%。
AstraZeneca PLC持有股份：387.33K，占总股份比例：5.86%。